about
sameAs
Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile: a tertiary cancer centre series analysis.Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial.Targeted therapy in head and neck cancer.Therapeutic strategies in the management of patients with metastatic anaplastic thyroid cancer: review of the current literature.Fosbretabulin for the treatment of anaplastic thyroid cancer.Postoperative radiotherapy with volumetric modulated arc therapy of lacrimal gland carcinoma: two case reports and literature review.Health care-associated infections in patients with head and neck cancer treated with chemotherapy and/or radiotherapy.Multikinase inhibitors in thyroid cancer.Safety of combination treatment with imatinib mesylate, carboplatin, and cetuximab in a patient with multiple cancers: a case report.Temporal course and predictive factors of analgesic opioid requirement for chemoradiation-induced oral mucositis in oropharyngeal cancer.Does a multidisciplinary team approach in a tertiary referral centre impact on the initial management of head and neck cancer?A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma.Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy.Fentanyl pectin nasal spray as treatment for incident predictable breakthrough pain (BTP) in oral mucositis induced by chemoradiotherapy in head and neck cancer.Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study.Rapid-onset opioids for the treatment of breakthrough cancer pain: two cases of drug abuse.Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancerComment on “Acute toxicity of three versus two courses of cisplatin for radiochemotherapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN): A matched pair analysis”, by Rades et coll
P50
Q30650708-58029962-F99C-450E-B450-A239A172E3DCQ34658767-138BAAA8-5055-4EF0-835F-08D0230617E0Q37849554-68D93D1F-D608-4881-A2A3-EDCDED67DB3EQ38089549-422DCD98-BF7F-4FFA-8C7E-4868FD20954EQ38268163-3779235E-9CCB-4CCD-A5CB-862BD336DF64Q38282447-CCFC7058-2943-4E0C-9E26-B31294249CC8Q39253334-85E58999-003E-4DDC-99C7-55F3792BF639Q39737306-CDC91767-C492-47E1-867E-440AAEA5CDE1Q39919172-7803F63D-B1D8-4A06-9256-ADE6B477F06AQ40020541-6FEF20BF-EE71-4E96-8326-F1FA0A6D6AC6Q40099914-985FD8EF-F8FF-437C-9E21-8522399DE183Q40485928-137B65F5-48A3-4CD7-A67F-EECD0311D046Q40527255-A4BAA188-EB47-4F18-A242-CE3711212CA7Q40539847-9F97B321-BF21-4F99-B02B-7164EE46A644Q42461792-E0D56129-F648-44F1-A754-334CA5185B26Q44480773-10AA7F64-7C72-4A06-9B71-405E3509A2A6Q47851937-F539A9E0-727C-4E6A-8AC6-E00B07DCC5CBQ59647709-111B7B7B-1FB5-4AA8-BC80-22CE5AD57B91Q60637511-3ED223EA-28E9-4134-A301-60A1719BA9DF
P50
description
researcher ORCID ID = 0000-0001-6584-3138
@en
wetenschapper
@nl
name
Roberta Granata
@ast
Roberta Granata
@en
Roberta Granata
@es
Roberta Granata
@nl
type
label
Roberta Granata
@ast
Roberta Granata
@en
Roberta Granata
@es
Roberta Granata
@nl
prefLabel
Roberta Granata
@ast
Roberta Granata
@en
Roberta Granata
@es
Roberta Granata
@nl
P106
P1153
36143118100
P21
P31
P496
0000-0001-6584-3138